Linked Life Data

14764679

Source:http://linkedlifedata.com/resource/pubmed/id/14764679

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14764679rdf:typepubmed:Citationlld:pubmed
pubmed-article:14764679lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C2350332lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C1420652lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C0056912lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C1522538lld:lifeskim
pubmed-article:14764679lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:14764679pubmed:issue4lld:pubmed
pubmed-article:14764679pubmed:dateCreated2004-2-6lld:pubmed
pubmed-article:14764679pubmed:abstractTextIdeal vaccines should be stable, safe, molecularly defined, and out-of-shelf reagents efficient at triggering effector and memory Ag-specific T cell-based immune responses. Dendritic cell-derived exosomes could be considered as novel peptide-based vaccines because exosomes harbor a discrete set of proteins, bear functional MHC class I and II molecules that can be loaded with synthetic peptides of choice, and are stable reagents that were safely used in pioneering phase I studies. However, we showed in part I that exosomes are efficient to promote primary MHC class I-restricted effector CD8(+) T cell responses only when transferred onto mature DC in vivo. In this work, we bring evidence that among the clinically available reagents, Toll-like receptor 3 and 9 ligands are elective adjuvants capable of triggering efficient MHC-restricted CD8(+) T cell responses when combined to exosomes. Exosome immunogenicity across species allowed to verify the efficacy of good manufactory procedures-manufactured human exosomes admixed with CpG oligonucleotides in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice. CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines.lld:pubmed
pubmed-article:14764679pubmed:languageenglld:pubmed
pubmed-article:14764679pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:citationSubsetAIMlld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14764679pubmed:statusMEDLINElld:pubmed
pubmed-article:14764679pubmed:monthFeblld:pubmed
pubmed-article:14764679pubmed:issn0022-1767lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:ZitvogelLaure...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:MeradMiriamMlld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:TaïebJulienJlld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:EscudierBerna...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:FerrantiniMar...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:TurszThomasTlld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:AngevinEricElld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:CarpentierAnt...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:ChaputNathali...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:AndréFabriceFlld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:BernardJackyJlld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:LemonnierFran...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:AdemaGosseGlld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:SchartzNöel...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:AubertNathali...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:NovaultSophie...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:BonnaventureP...lld:pubmed
pubmed-article:14764679pubmed:authorpubmed-author:AdamsMalcolmMlld:pubmed
pubmed-article:14764679pubmed:issnTypePrintlld:pubmed
pubmed-article:14764679pubmed:day15lld:pubmed
pubmed-article:14764679pubmed:volume172lld:pubmed
pubmed-article:14764679pubmed:ownerNLMlld:pubmed
pubmed-article:14764679pubmed:authorsCompleteYlld:pubmed
pubmed-article:14764679pubmed:pagination2137-46lld:pubmed
pubmed-article:14764679pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:meshHeadingpubmed-meshheading:14764679...lld:pubmed
pubmed-article:14764679pubmed:year2004lld:pubmed
pubmed-article:14764679pubmed:articleTitleExosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.lld:pubmed
pubmed-article:14764679pubmed:affiliationUnité d'Immunologie, ERM0208 Institut National de la Santé et de la Recherche Médicale, Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France.lld:pubmed
pubmed-article:14764679pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14764679pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14764679lld:pubmed
More...